World Aquaculture Singapore 2026

June 2-5, 2026

Singapore

EFFICACY OF THE TETRAVALENT VACCINE ALPHAJECT® MICRO4 IN RAINBOW TROUT Oncorhynchus mykiss AGAINST JAPANESE ISOLATES OF Aeromonas salmonicida, Vibrioanguillarum  O1 AND O2a

Rolf Hetlelid Olsen*, Takeshi Fujii, Miki Sugiyama, Sara Rodenberg, Tone Madsen, Magnus Knape, Børge Nilsen Fredriksen

 

PHARMAQ part of Zoetis
Thormøhlensgate 53d, N-5006 Bergen, Norway
rolf.hetlelid-olsen@zoetis.com



A growing aquaculture industry is a prerequisite for sufficient protein production for a constantly growing world population. Farming of fish is by far the most sustainable way of producing proteins for human consumption, compared to industrialised terrestrial farming. As with other animal species, fish kept in a farming situation are susceptible to diseases – often treated with antibiotics. In the Norwegian salmon industry, the introduction of efficacious vaccines in the late eighties dramatically reduced the demand for antibiotics. And the industry did not hesitate to shift into a strategy of prevention rather than treatment. In Norway today, no farmed salmonids are put into sea cages without first being vaccinated with one or more vaccines.

Today Japan has a stable production of approx. 5000 tons of Rainbow trout annually. But diseases like vibriosis and furunculosis account for a loss of around 6%. Furunculosis is caused by the bacterium Aeromonas salmonicida and Vibriosis is caused by the bacteria Vibrio anguillarum serotype O1 and O2α. Although a dip vaccine against vibriosis in salmonids is licensed in Japan, the disease situation is still not under control.

In this presentation we will show the efficacy of an inactivated oil-adjuvanted vaccine used in rainbow trout after experimental challenges with Japanese isolates of Aeromonas salmonicida, Vibrio anguillarum serotype O1 and O2α.